<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Destruction | Clinical Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Thrombocytopenias due to Increased Destruction Definition of Thrombocytopenia: Abnormally low platelet count, defined as a platelet count less than 150 x 10^9/L (150,000/µL) Clinical...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Destruction | Clinical Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Thrombocytopenias due to Increased Destruction Definition of Thrombocytopenia: Abnormally low platelet count, defined as a platelet count less than 150 x 10^9/L (150,000/µL) Clinical...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Destruction | Clinical Hematology">
<meta name="twitter:description" content="Overview of Thrombocytopenias due to Increased Destruction Definition of Thrombocytopenia: Abnormally low platelet count, defined as a platelet count less than 150 x 10^9/L (150,000/µL) Clinical...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Clinical Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="active" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="destruction" class="section level1 unnumbered">
<h1>Destruction<a class="anchor" aria-label="anchor" href="#destruction"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-thrombocytopenias-due-to-increased-destruction" class="section level2 unnumbered">
<h2>
<strong>Overview of Thrombocytopenias due to Increased Destruction</strong><a class="anchor" aria-label="anchor" href="#overview-of-thrombocytopenias-due-to-increased-destruction"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li><p><strong>Definition of Thrombocytopenia:</strong> Abnormally low platelet count, defined as a platelet count less than 150 x 10^9/L (150,000/µL)</p></li>
<li><p><strong>Clinical Significance:</strong> Increases the risk of bleeding, ranging from minor skin bruising to severe or life-threatening hemorrhages</p></li>
<li>
<p><strong>Major Causes of Thrombocytopenia Due to Increased Destruction (Immune and Non-Immune):</strong></p>
<ul>
<li>Immune Thrombocytopenic Purpura (ITP)</li>
<li>Thrombotic Thrombocytopenic Purpura (TTP)</li>
<li>Heparin-Induced Thrombocytopenia (HIT)</li>
<li>Disseminated Intravascular Coagulation (DIC): Consumptive Coagulopathy, may also be due to non-immune consumptive process</li>
<li>Hemolytic Uremic Syndrome (HUS)</li>
</ul>
</li>
<li>
<p><strong>General Laboratory Findings:</strong></p>
<ul>
<li>Reduced platelet count.</li>
<li>Normal or increased megakaryocytes in the bone marrow (in thrombocytopenias due to increased destruction)</li>
<li>Prolonged bleeding time and/or abnormal platelet function tests</li>
<li>Other findings specific to each disorder (see below)</li>
</ul>
</li>
</ul>
</div>
<div id="immune-thrombocytopenic-purpura-itp" class="section level2 unnumbered">
<h2>
<strong>Immune Thrombocytopenic Purpura (ITP)</strong><a class="anchor" aria-label="anchor" href="#immune-thrombocytopenic-purpura-itp"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> An acquired autoimmune disorder characterized by isolated thrombocytopenia (low platelet count) with normal bone marrow and no other causes of thrombocytopenia</li>
<li>
<strong>Also Known As:</strong> Idiopathic Thrombocytopenic Purpura</li>
<li>
<strong>Types:</strong>
<ul>
<li>Primary ITP: No identifiable underlying cause</li>
<li>Secondary ITP: Associated with underlying conditions, such as:
<ul>
<li>Autoimmune disorders (e.g., SLE, rheumatoid arthritis)</li>
<li>Infections (e.g., HIV, hepatitis C, <em>Helicobacter pylori</em>)</li>
<li>Lymphoproliferative disorders (e.g., CLL)</li>
<li>Medications</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Autoantibody Production: Autoantibodies (typically IgG) are produced against platelet membrane glycoproteins (e.g., GPIIb/IIIa, GPIb/IX)</li>
<li>Platelet Destruction: Antibody-coated platelets are recognized and destroyed by macrophages in the spleen (extravascular hemolysis)</li>
<li>Impaired Platelet Production: Some autoantibodies may also target megakaryocytes, impairing platelet production</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Many patients are asymptomatic</li>
<li>Bleeding Manifestations:
<ul>
<li>Petechiae (small, pinpoint hemorrhages)</li>
<li>Purpura (bruising)</li>
<li>Nosebleeds (epistaxis)</li>
<li>Gum bleeding</li>
<li>Menorrhagia (heavy menstrual periods)</li>
<li>Gastrointestinal bleeding (less common)</li>
<li>Intracranial hemorrhage (rare but life-threatening)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>Complete Blood Count (CBC):
<ul>
<li>Isolated thrombocytopenia (platelet count &lt;150 x 10^9/L)</li>
<li>Normal hemoglobin, white blood cell count, and differential</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Decreased number of platelets</li>
<li>May see large platelets (megathrombocytes), reflecting increased platelet production by the bone marrow</li>
<li>No other significant abnormalities (e.g., schistocytes, blasts)</li>
</ul>
</li>
<li>Bone Marrow Aspiration and Biopsy (Not always necessary; usually performed to rule out other causes of thrombocytopenia):
<ul>
<li>Normal or increased megakaryocytes (platelet precursors)</li>
<li>Normal cellularity and maturation of other cell lines</li>
</ul>
</li>
<li>Direct Antibody Test (DAT) for Platelets:
<ul>
<li>Detects the presence of anti-platelet antibodies</li>
<li>Not always performed, as the sensitivity and specificity of these tests are limited</li>
</ul>
</li>
<li>Exclusion of Other Causes of Thrombocytopenia:
<ul>
<li>Rule out drug-induced thrombocytopenia, TTP, HUS, DIC, and other conditions that can cause thrombocytopenia</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Diagnosis:</strong> Diagnosis of exclusion. ITP is diagnosed when other causes of thrombocytopenia have been ruled out and is supported by normal or increased megakaryocytes in the bone marrow</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Observation: Mild thrombocytopenia in asymptomatic patients may not require immediate treatment</li>
<li>Corticosteroids: Prednisone or dexamethasone
<ul>
<li>Suppress autoantibody production and decrease platelet destruction</li>
<li>First-line treatment for symptomatic ITP</li>
</ul>
</li>
<li>Intravenous Immunoglobulin (IVIG):
<ul>
<li>Used to rapidly increase the platelet count in patients with significant bleeding or requiring urgent surgery</li>
<li>Mechanism: Blocks Fc receptors on macrophages, reducing platelet destruction</li>
</ul>
</li>
<li>Anti-D Immunoglobulin (WinRho):
<ul>
<li>Used in Rh-positive patients with ITP</li>
<li>Mechanism: Antibody-coated RBCs are then cleared by the spleen, “sparing” the platelets from destruction</li>
</ul>
</li>
<li>Rituximab:
<ul>
<li>Anti-CD20 monoclonal antibody that depletes B cells, reducing autoantibody production</li>
<li>Used in patients who are refractory to corticosteroids and IVIG</li>
</ul>
</li>
<li>Thrombopoietin Receptor Agonists (TPO-RAs):
<ul>
<li>Eltrombopag and romiplostim</li>
<li>Stimulate platelet production by binding to and activating the thrombopoietin receptor on megakaryocytes</li>
<li>Used in patients who have failed other treatments</li>
</ul>
</li>
<li>Splenectomy:
<ul>
<li>Surgical removal of the spleen</li>
<li>Used in patients with severe, refractory ITP</li>
<li>Increases the risk of infection with encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis)</li>
<li>Patients require vaccination before splenectomy</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="thrombotic-thrombocytopenic-purpura-ttp" class="section level2 unnumbered">
<h2>
<strong>Thrombotic Thrombocytopenic Purpura (TTP)</strong><a class="anchor" aria-label="anchor" href="#thrombotic-thrombocytopenic-purpura-ttp"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A life-threatening thrombotic microangiopathy (TMA) characterized by microangiopathic hemolytic anemia (MAHA) and thrombocytopenia</li>
<li>
<strong>Hallmark:</strong> Pentad of Thrombocytopenia, Microangiopathic Hemolytic Anemia, Neurologic Abnormalities, Fever, and Renal Abnormalities</li>
<li>
<strong>Types:</strong>
<ul>
<li>Acquired TTP:
<ul>
<li>Autoimmune: Antibodies against ADAMTS13</li>
<li>Idiopathic: No known underlying cause</li>
<li>Secondary: Associated with pregnancy, autoimmune disorders, medications, or stem cell transplantation</li>
</ul>
</li>
<li>Hereditary TTP (Upshaw-Schulman Syndrome):
<ul>
<li>Inherited deficiency of ADAMTS13</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>ADAMTS13 Deficiency: Reduced or absent activity of ADAMTS13, a metalloprotease that cleaves von Willebrand factor (vWF)</li>
<li>vWF Multimer Accumulation: Ultra-large vWF multimers accumulate in the microvasculature</li>
<li>Platelet Activation and Microthrombi Formation: vWF multimers bind to platelets, leading to platelet activation, aggregation, and the formation of microthrombi in small blood vessels</li>
<li>Microangiopathic Hemolytic Anemia (MAHA): RBCs are damaged as they pass through the microthrombi, resulting in fragmentation (schistocytes) and hemolysis</li>
<li>Thrombocytopenia: Platelets are consumed in the formation of microthrombi</li>
<li>Organ Ischemia: Microthrombi obstruct blood flow to vital organs (brain, kidneys, heart), leading to organ damage</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Thrombocytopenia: Bleeding manifestations (petechiae, purpura, etc.)</li>
<li>Microangiopathic Hemolytic Anemia (MAHA): Fatigue, pallor, jaundice</li>
<li>Neurologic Abnormalities: Headache, confusion, seizures, stroke</li>
<li>Fever</li>
<li>Renal Abnormalities: Elevated creatinine, hematuria, proteinuria</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Thrombocytopenia (platelet count &lt;150 x 10^9/L)</li>
<li>Anemia (decreased HGB and HCT)</li>
<li>Increased reticulocyte count</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Schistocytes (fragmented RBCs)</li>
<li>Polychromasia (increased reticulocytes)</li>
<li>Decreased platelets</li>
</ul>
</li>
<li>Coagulation Studies:
<ul>
<li>PT and aPTT: Usually normal</li>
<li>Fibrinogen: Normal or slightly increased</li>
<li>D-dimer: May be elevated</li>
</ul>
</li>
<li>Lactate Dehydrogenase (LDH): Elevated (due to hemolysis)</li>
<li>Indirect Bilirubin: Elevated (due to hemolysis)</li>
<li>Haptoglobin: Decreased (due to hemolysis)</li>
<li>Creatinine: Elevated (due to renal involvement)</li>
<li>ADAMTS13 Activity Assay:
<ul>
<li>Markedly reduced (&lt;10% of normal) in most cases of acquired TTP</li>
<li>Absent in hereditary TTP</li>
</ul>
</li>
<li>ADAMTS13 Inhibitor Assay:
<ul>
<li>Detects the presence of autoantibodies against ADAMTS13</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Diagnosis:</strong> Diagnosis of TTP requires prompt recognition and treatment</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Plasma Exchange:
<ul>
<li>Mainstay of treatment</li>
<li>Removes vWF multimers and replaces ADAMTS13</li>
</ul>
</li>
<li>Corticosteroids:
<ul>
<li>To suppress autoantibody production</li>
</ul>
</li>
<li>Rituximab:
<ul>
<li>Anti-CD20 monoclonal antibody that depletes B cells and reduces autoantibody production</li>
</ul>
</li>
<li>Caplacizumab:
<ul>
<li>A humanized nanobody that binds to vWF and inhibits its interaction with platelets</li>
<li>Reduces the risk of thrombotic events and shortens the duration of plasma exchange</li>
</ul>
</li>
<li>Avoid Platelet Transfusions: Platelet transfusions may exacerbate the thrombotic process and are generally avoided unless life-threatening bleeding occurs</li>
</ul>
</li>
</ul>
</div>
<div id="heparin-induced-thrombocytopenia-hit" class="section level2 unnumbered">
<h2>
<strong>Heparin-Induced Thrombocytopenia (HIT)</strong><a class="anchor" aria-label="anchor" href="#heparin-induced-thrombocytopenia-hit"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A potentially life-threatening immune-mediated disorder characterized by thrombocytopenia and an increased risk of thrombosis following exposure to heparin</li>
<li>
<strong>Types:</strong>
<ul>
<li>Type I HIT (Non-Immune): Mild, transient thrombocytopenia occurring within the first 2 days of heparin exposure. Not clinically significant</li>
<li>Type II HIT (Immune-Mediated):
<ul>
<li>Antibodies against heparin-platelet factor 4 (PF4) complex, leading to platelet activation and thrombosis</li>
<li>Clinically significant and associated with a high risk of venous and arterial thrombosis</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Heparin-PF4 Complex Formation: Heparin binds to platelet factor 4 (PF4), a positively charged protein released from platelets</li>
<li>Antibody Production: Patients develop IgG antibodies against the heparin-PF4 complex</li>
<li>Platelet Activation: IgG antibodies bind to the heparin-PF4 complex on platelet surfaces, leading to platelet activation and aggregation via FcγIIa receptors</li>
<li>Thrombosis: Activated platelets release procoagulant factors, leading to thrombin generation and thrombosis</li>
<li>Thrombocytopenia: Platelets are consumed in the formation of thrombi and cleared from the circulation</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Thrombocytopenia: Typically occurs 5-10 days after starting heparin (but can occur earlier with prior heparin exposure)</li>
<li>Thrombosis: Venous and arterial thromboembolic events (e.g., DVT, pulmonary embolism, stroke, limb ischemia, skin necrosis)</li>
<li>Skin Necrosis at Heparin Injection Sites</li>
<li>Systemic Reactions: Chills, fever, dyspnea (less common)</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Thrombocytopenia (platelet count typically &lt;150 x 10^9/L, but can be variable)</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Usually normal; may see large platelets</li>
</ul>
</li>
<li>HIT Antibody Testing:
<ul>
<li>Screening Assay: ELISA or immunoturbidimetric assay to detect antibodies against heparin-PF4 complex (high sensitivity, but lower specificity)</li>
<li>Confirmatory Assay: Serotonin Release Assay (SRA) or Heparin-Induced Platelet Activation (HIPA) assay (high specificity)</li>
</ul>
</li>
<li>Coagulation Studies:
<ul>
<li>aPTT: May be prolonged, normal, or shortened</li>
</ul>
</li>
<li>D-dimer: Elevated</li>
</ul>
</li>
<li>
<strong>Diagnosis:</strong> 4Ts Scoring System
<ul>
<li>Thrombocytopenia: Degree and timing of platelet count fall</li>
<li>Timing: When did the thrombocytopenia occur in relation to Heparin use</li>
<li>Thrombosis: Presence of new thrombosis or skin necrosis</li>
<li>Other Causes for Thrombocytopenia: Absence of other obvious causes of thrombocytopenia</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Stop Heparin Immediately: This is the <em>most</em> important step</li>
<li>Administer Alternative Anticoagulant:
<ul>
<li>Direct Thrombin Inhibitors (DTIs): Argatroban, bivalirudin</li>
<li>Fondaparinux: A synthetic pentasaccharide that inhibits factor Xa</li>
</ul>
</li>
<li>Avoid Platelet Transfusions: Platelet transfusions may exacerbate thrombosis in HIT</li>
<li>Warfarin: Should be avoided acutely due to the risk of venous limb gangrene; can be initiated once the platelet count has recovered and the patient is on a stable dose of a non-heparin anticoagulant</li>
</ul>
</li>
</ul>
</div>
<div id="key-terms-38" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-38"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Thrombocytopenia:</strong> Decreased platelet count (&lt;150 x 10^9/L)</li>
<li>
<strong>ITP (Immune Thrombocytopenic Purpura):</strong> Autoimmune destruction of platelets</li>
<li>
<strong>TTP (Thrombotic Thrombocytopenic Purpura):</strong> Microangiopathic hemolytic anemia and thrombocytopenia due to ADAMTS13 deficiency</li>
<li>
<strong>HUS (Hemolytic Uremic Syndrome):</strong> Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury</li>
<li>
<strong>DIC (Disseminated Intravascular Coagulation):</strong> Systemic activation of coagulation and fibrinolysis</li>
<li>
<strong>Schistocytes:</strong> Fragmented red blood cells</li>
<li>
<strong>ADAMTS13:</strong> A metalloprotease that cleaves von Willebrand factor (vWF)</li>
<li>
<strong>Heparin-Induced Thrombocytopenia (HIT):</strong> Immune-mediated thrombocytopenia caused by antibodies against heparin-PF4 complex</li>
<li>
<strong>Heparin-Platelet Factor 4 (PF4) Complex:</strong> Target for antibodies in HIT</li>
<li>
<strong>Haptoglobin:</strong> Protein that binds free hemoglobin released into the plasma</li>
<li>
<strong>Microangiopathic Hemolytic Anemia (MAHA):</strong> Hemolytic anemia caused by mechanical destruction of RBCs in small blood vessels</li>
</ul>
</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="thrombocytopenia-1.html">Thrombocytopenia</a></div>
<div class="next"><a href="production.html">Production</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#destruction">Destruction</a></li>
<li><a class="nav-link" href="#overview-of-thrombocytopenias-due-to-increased-destruction">Overview of Thrombocytopenias due to Increased Destruction</a></li>
<li><a class="nav-link" href="#immune-thrombocytopenic-purpura-itp">Immune Thrombocytopenic Purpura (ITP)</a></li>
<li><a class="nav-link" href="#thrombotic-thrombocytopenic-purpura-ttp">Thrombotic Thrombocytopenic Purpura (TTP)</a></li>
<li><a class="nav-link" href="#heparin-induced-thrombocytopenia-hit">Heparin-Induced Thrombocytopenia (HIT)</a></li>
<li><a class="nav-link" href="#key-terms-38">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/main/03-06-platelet-quantitative-thrombocytopenia-destruction.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/edit/main/03-06-platelet-quantitative-thrombocytopenia-destruction.Rmd">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-20 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
